 |
Tomasz NadolskiA Pole with Fabry disease
Date of Birth: 01.01.1993
Country:  Poland |
Content:
- Tomasz Nadolski: A 25-Year-Old with the Appearance of a 12-Year-Old
- Appearance and Social Impact
- Symptoms and Treatment
- Hope in New Treatments
Tomasz Nadolski: A 25-Year-Old with the Appearance of a 12-Year-Old
Early Life and DiagnosisTomasz Nadolski, 25-year-old from Olesnica, Poland, suffers from a rare genetic disease called Fabry disease. At the age of seven, Tomasz began experiencing vomiting and pain in his abdomen, arms, and legs. Doctors struggled to diagnose his condition, initially suspecting psychological issues. His parents, misled by the prognosis, believed his "eating disorder" could be resolved by force-feeding him.
Appearance and Social Impact
Fabry disease affects Tomasz's appearance, giving him the physical characteristics of a 12-year-old child. This has had a profound impact on his social interactions. "I feel lonely and I lack support from my family," he confides. "The disease has destroyed our family relationships." Tomasz faces skepticism when presenting his ID or interacting with police, who often accuse him of forgery due to his youthful appearance.
Symptoms and Treatment
Fabry disease belongs to a group of lysosomal storage diseases. It affects multiple organs, including the kidneys, heart, and skin, due to the accumulation of a specific type of fat, globotriaosylceramide (Gb3), within cells. Tomasz receives free treatment for his condition, which includes 20 hours of daily intravenous infusions and morphine patches to manage his severe pain. Due to stomach issues, he cannot eat normally and relies solely on liquid nutrition.
Hope in New Treatments
Consultant physician Atul Mehta explains that Fabry disease results from a genetic defect that affects the production of a protein responsible for breaking down cellular waste products. This leads to the accumulation of fat in various cells, causing kidney problems, heart enlargement, nerve damage, and blood vessel narrowing.
Mehta's research aims to target the disease at its core by introducing corrected forms of the defective gene using DNA technology. This treatment has the potential to increase the production of the missing protein and alleviate the symptoms associated with Fabry disease.
